Advocacy Group Says a Medicare Rule Change Delayed Price Negotiation for a Costly AbbVie Drug by Seven Years
Public Citizen says a CMS eligibility change kept AbbVie's Creon out of Medicare price negotiation for seven extra years. Here is how it works.
Medical Daily ·